Table 3 Prevalence of antinuclear-associated autoantibodies in serum and in corresponding immune complexes (IC).

From: Accumulation of antinuclear associated antibodies in circulating immune complexes is more prominent in SLE patients from Sudan than Sweden

ANA

Serum

IC

Sudan, n (%)

Sweden, n (%)

P

Sudan, n (%)

Sweden, n (%)

P

SSA/Ro52

30(32.2)

105(31.7)

0.9

18(19.3)

55(16.6)

0.5

SSA/Ro60

34(36.6)

122(36.9)

0.9

27(29)

89(26.8)

0.7

SSB/La

15(16.1)

64(19.3)

0.5

9(9.7)

38(11.4)

0.3

Sm

12(12.9)

21(6.3)

0.04

6(6.4)

5(1.5)

0.008

Sm/U1RNP

15(16.1)

42(12.7)

0.4

17(18.3)

33(9.9)

0.03

U1RNP

20(21.5)

69(20.8)

0.9

22(23.7)

55(16.6)

0.1

dsDNA

31(33.3)

147(44.4)

0.055

64(68.8)

105(31.6)

 < 0.0001

Histone

10(10.7)

34(10.3)

0.9

34(36.6)

58(17.5)

 < 0.0001

Ribosomal P

4(4.3)

20(6)

0.5

2(2.1)

9(2.7)

0.8

PCNA

1(1.1)

10(3)

0.3

20(21.5)

45(13.5)

0.06

  1. Significant P values are depicted in bold and underlined to indicate higher levels in Sudanese patients.
Back to article page